MK0524A Phase IIb Study (0524A-011)(COMPLETED)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00536237|
Recruitment Status : Completed
First Posted : September 27, 2007
Last Update Posted : August 25, 2015
Part A: This study will determine that MK0524 is well tolerated and does not effect lipids and blood glucose when given alone.
Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids and blood glucose.
|Condition or disease||Intervention/treatment||Phase|
|Flushing||Drug: Comparator: niacin / Duration of Treatment: 17 Weeks Drug: MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks Drug: Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||154 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on Niacin-Induced Flushing in Lipid Clinic Patients|
|Study Start Date :||August 2004|
|Actual Primary Completion Date :||February 2005|
|Actual Study Completion Date :||December 2006|
- To determine the effect of MK0524A on lipids and blood glucose [ Time Frame: 17 Weeks ]
- To establish the dose for limiting flushing symptoms induced by NIASPAN (R) [ Time Frame: 17 Weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00536237
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|